Annual Drug Patent Expirations for CALQUENCE
Calquence is a drug marketed by Astrazeneca and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug.
Drug patent litigation for CALQUENCE.
This drug has one hundred and forty-five patent family members in forty-nine countries.
The generic ingredient in CALQUENCE is acalabrutinib maleate. One supplier is listed for this compound. Additional details are available on the acalabrutinib maleate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
